PROJECT NARRATIVE Fragile X syndrome (FXS) is a genetic disorder that is the most common inherited cause of intellectual disability and often comorbid with autism spectrum disorder (ASD). Epigenetic silencing of the FMR1 gene in FXS results in a deficiency of the Fragile X mental retardation protein (FMRP), a binding protein that activates Slack potassium channels. Drugs that activate Slack channels may provide effective treatments for FXS, and potent and selective Slack activator cell-based probes are required to validate this therapeutic approach.
|Effective start/end date||1/12/20 → 31/10/22|
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.